{"data":{"id":2454,"lang":"en","title":"CRISPR Therapy Cuts Bad Cholesterol in Half for a Full Year, Trial Finds","summary":"A single CRISPR gene-editing infusion cut LDL cholesterol by over half for a year in a first-in-human trial, with no serious side effects.","category":"science","category_label":"Science","published_at":"2026-09-28T10:01:48Z","updated_at":"2026-09-28T10:01:48Z","url":"https://techtools.cz/tools/news/article/2454-crispr-therapy-cuts-bad-cholesterol-in-half-for-a-full-year-trial-finds","api_url":"https://techtools.cz/news-api/v1/articles/2454?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/2454.md?lang=en","image_url":"https://assets.clevelandclinic.org/transform/3c736bac-1b7b-42fc-be80-6d9c3cd7dbd3/crispr-laffin","word_count":139,"reading_time_minutes":1,"sources":[{"url":"https://newsroom.clevelandclinic.org/2026/08/28/cleveland-clinic-first-in-human-trial-of-crispr-gene-editing-therapy-shown-to-safely-and-continuously-lower-cholesterol-and-triglycerides-after-one-year","domain":"newsroom.clevelandclinic.org"},{"url":"https://www.sciencedaily.com/releases/2026/09/260925005434.htm","domain":"sciencedaily.com"}],"translation":{"lang":"cs","id":2528,"title":"Terapie CRISPR snížila špatný cholesterol o polovinu na celý rok, ukazuje studie","url":"https://techtools.cz/tools/news/clanek/2528-terapie-crispr-snizila-spatny-cholesterol-o-polovinu-na-cely-rok-ukazuje-studie","api_url":"https://techtools.cz/news-api/v1/articles/2528?lang=cs"},"content":"Cleveland Clinic cardiologist Luke Laffin led a first-in-human Phase 1 trial testing CTX310, an experimental CRISPR-Cas9 gene-editing therapy from CRISPR Therapeutics, in patients with lipid disorders that had not responded to standard medication.\n\nA single one-time infusion of CTX310 switches off the ANGPTL3 gene in the liver. Among the 15 participants, those who received the highest dose showed a 52.5% reduction in LDL cholesterol and a 47.8% drop in triglycerides after 12 months, with no serious adverse events reported during follow-up.\n\nThe results, presented at the European Society of Cardiology's 2026 congress and published in the New England Journal of Medicine, suggest a single treatment could replace a lifetime of daily cholesterol-lowering pills for people with hard-to-treat lipid disorders linked to heart attacks and stroke. Researchers plan to monitor participants for 15 years to confirm the therapy's long-term safety."}}